About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Alzheimer's Disease Clinical Trials in Phoenix | 242 Studies

Clinical Trials Alzheimer's DiseasePhoenix

Alzheimer's Disease Clinical Trials in Phoenix

Find 242 clinical trials for alzheimer's disease near Phoenix, Arizona. Connect with research centers in your area.

All Alzheimer's Disease trials nationwide All trials in Phoenix

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 21-40 of 242 trials

CompletedRosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's DiseaseRosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to…NCT00348309·Litchfield Park, Arizona and 248 others

Alzheimer's Disease Trials in Other Cities

New York Los Angeles Chicago Houston Philadelphia San Antonio

Data from ClinicalTrials.govTerms

TerminatedA Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's DiseaseThe main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).NCT02760602·Phoenix, Arizona and 192 others

Enrolling by invitationExtension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study.NCT06245031·Phoenix, Arizona and 52 others

TerminatedContinued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's DiseaseThis study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN…NCT01127633·Phoenix, Arizona and 146 others

CompletedEfficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's DiseaseThe objectives of the study are to evaluate the safety, tolerability and efficacy of AVP-923 compared to placebo, for the treatment of symptoms of agitation in participants with…NCT01584440·Phoenix, Arizona and 43 others

CompletedA Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's DiseaseThe purpose of this study is to evaluate the efficacy and safety of PF 04494700 in participants with mild to moderate Alzheimer's disease.NCT00566397·Phoenix, Arizona and 61 others

CompletedHuperzine A in Alzheimer's DiseaseThe present study will evaluate the safety and efficacy of the Chinese herb huperzine A in the treatment of Alzheimer's disease (AD) in a randomized controlled trial of its effect…NCT00083590·Birmingham, Alabama and 28 others

Active not recruitingA Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the…NCT06223360·Phoenix, Arizona and 46 others

RecruitingA Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses.NCT07602582·Phoenix, Arizona and 61 others

TerminatedA Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's DiseaseThe purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical…NCT02565511·Phoenix, Arizona and 128 others

CompletedA Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseA phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.NCT04592874·Phoenix, Arizona and 86 others

CompletedA Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.NCT04777409·Phoenix, Arizona and 497 others

CompletedCholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease StudyCLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of Alzheimer's disease (AD).NCT00053599·Birmingham, Alabama and 43 others

CompletedEffects of ONO-2506PO in Patients With Alzheimer's DiseaseThe purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.NCT00083421·Birmingham, Alabama and 86 others

UnknownArizona Alzheimer's Disease Research Center (ADRC)The Arizona Alzheimer's Disease Research Center (ADRC) is the National Institute on Aging's (NIA's) first statewide AD Center (ADC), the only ADC in the Southwestern United…NCT05405075·Phoenix, Arizona and 4 others

CompletedDHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's DiseaseThe purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate…NCT00440050·Birmingham, Alabama and 50 others

CompletedSUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a StudyThis is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with…NCT02580305·Phoenix, Arizona and 70 others

CompletedA Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's DiseaseAZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation.NCT02167256·Phoenix, Arizona and 21 others

CompletedEffectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive DeclineThis study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.NCT01703702·Phoenix, Arizona and 56 others

TerminatedA Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's DiseaseThe purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study…NCT00937352·Birmingham, Alabama and 190 others

PreviousPage 2 of 13Next

Other Conditions in Phoenix

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia